RxDoctor Payments DataLook up a doctor →

Nicolas Saikali, MD

Neurology · Amherst, NYNPI 1821228511

Payments from drug & device makers

$1,805,782in general payments, 2019–2025

Across 3,443 payments — averaging $524.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$850K
  • Amgen$195K
  • Teva Pharmaceuticals USA, Inc.$159K
  • Neurology Practice Consortium GPO, LLC$142K
  • Lundbeck LLC$112K
  • Biohaven Pharmaceuticals, Inc.$110K
  • plus $237K from 54 others
$5,158in research payments, 2019–2025

Across 3 payments — averaging $1719.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K

What the payments were for

  • Consulting fees$229,00215%
  • Speaking & faculty fees$1,141,61576%
  • Grants$420%
  • Travel & lodging$80,5305%
  • Food & beverage$59,6754%
  • Education$3380%
  • Gifts$3000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)1,016$850,028
Amgen(2 entities)304$195,111
Teva Pharmaceuticals USA, Inc.208$158,545
Neurology Practice Consortium GPO, LLC7$142,176
Lundbeck LLC243$111,653
Biohaven Pharmaceuticals, Inc.222$110,471
Biohaven Pharmaceutical Holding Company Ltd.145$56,851
Impel Pharmaceuticals Inc.91$43,708
Axsome Therapeutics, Inc.52$42,857
H. Lundbeck A S16$35,050
Lilly USA, LLC101$14,961
Promius Pharma LLC23$10,653
Eli Lilly3$5,233
Bausch Health US, LLC4$3,750
Avanir Pharmaceuticals, Inc.11$3,390
Tonix Medicines, Inc.77$3,096
Pfizer45$2,623
Upsher-smith Laboratories LLC53$2,036
Livanova USA, Inc.46$1,717
MDD US Operations, LLC37$1,236
Supernus Pharmaceuticals, Inc.106$1,182
UCB, Inc.56$1,136
Novartis54$963
Assertio Therapeutics, Inc.98$827
Scilex Pharmaceuticals Inc.67$531
Eisai Inc.16$430
Zyla Life Sciences, Inc.68$399
AstraZeneca(2 entities)14$369
SK Life Science, Inc.15$363
Kestra Medical Technology Services, Inc.6$332
Jazz Pharmaceuticals Inc.9$291
Biogen11$245
GE HealthCare36$236
Currax Pharmaceuticals LLC13$228
Azurity Pharmaceuticals, Inc.14$223
Impel Pharmaceuticals LLC11$213
Neurocrine Biosciences, Inc.10$182
Ipsen Biopharmaceuticals, Inc8$178
Acadia Pharmaceuticals Inc10$160
Arbor Pharmaceuticals, Inc.10$154
Collegium Pharmaceutical, Inc.22$151
Banner Life Sciences, LLC7$130
Greenwich Biosciences, Inc.6$109
GRT US Holding, Inc.1$109
W. L. Gore & Associates, Inc.1$103
Harmony Biosciences LLC2$103
Merck5$90
Catalyst Pharmaceuticals, Inc.4$86
Amneal Pharmaceuticals LLC5$76
CSL Behring3$75
Boston Scientific2$68
Grifols USA, LLC3$66
Acorda Therapeutics, Inc3$64
Takeda Pharmaceuticals U.S.A., Inc.3$63
TG Therapeutics, Inc.3$60
Adamas Pharmaceuticals, Inc.3$57
Johnson & Johnson3$50
Averitas Pharma Inc.2$40
Sunovion Pharmaceuticals Inc.2$37
Tanabe Pharma America, Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,805,782 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$547,969
Medicare patients
126
Services billed
21,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate29$29,351
UbrelvyUbrogepant25$27,968
Emgality PenGalcanezumab-Gnlm23$19,943
Sumatriptan Succinate42$1,229
Pregabalin15$1,053
Amitriptyline Hcl36$585
RizatriptanRizatriptan Benzoate28$568
Nortriptyline Hcl38$403
Topiramate25$254
Divalproex Sodium ErDivalproex Sodium11$173
Gabapentin15$120
Tizanidine Hcl16$86
Cyclobenzaprine Hcl13$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$2,623$29,35129 claims
AbbVieUbrelvy$850,028$27,96825 claims
Upsher-smith Laboratories LLCTopiramate$2,036$25425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →